207 related articles for article (PubMed ID: 37344992)
1. Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy.
Miyamoto S; Hirohashi Y; Morita R; Miyazaki A; Ogi K; Kanaseki T; Ide K; Shirakawa J; Tsukahara T; Murai A; Sasaya T; Koike K; Kina S; Kawano T; Goto T; Ntege EH; Shimizu Y; Torigoe T
Cancer Sci; 2023 Sep; 114(9):3496-3508. PubMed ID: 37344992
[TBL] [Abstract][Full Text] [Related]
2. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract][Full Text] [Related]
3. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
5. The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.
Miyamoto S; Kochin V; Kanaseki T; Hongo A; Tokita S; Kikuchi Y; Takaya A; Hirohashi Y; Tsukahara T; Terui T; Ishitani K; Hata F; Takemasa I; Miyazaki A; Hiratsuka H; Sato N; Torigoe T
Cancer Immunol Res; 2018 Mar; 6(3):358-369. PubMed ID: 29371260
[TBL] [Abstract][Full Text] [Related]
6. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
[TBL] [Abstract][Full Text] [Related]
7. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
8. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.
Xu Q; Liu G; Yuan X; Xu M; Wang H; Ji J; Konda B; Black KL; Yu JS
Stem Cells; 2009 Aug; 27(8):1734-40. PubMed ID: 19536809
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell self-renewal as a therapeutic target in human oral cancer.
Hu J; Mirshahidi S; Simental A; Lee SC; De Andrade Filho PA; Peterson NR; Duerksen-Hughes P; Yuan X
Oncogene; 2019 Jul; 38(27):5440-5456. PubMed ID: 30936460
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.
Morita R; Nishizawa S; Torigoe T; Takahashi A; Tamura Y; Tsukahara T; Kanaseki T; Sokolovskaya A; Kochin V; Kondo T; Hashino S; Asaka M; Hara I; Hirohashi Y; Sato N
Cancer Sci; 2014 Apr; 105(4):389-95. PubMed ID: 24450541
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
12. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
[TBL] [Abstract][Full Text] [Related]
13. Cell division patterns and chromosomal segregation defects in oral cancer stem cells.
Kaseb HO; Lewis DW; Saunders WS; Gollin SM
Genes Chromosomes Cancer; 2016 Sep; 55(9):694-709. PubMed ID: 27123539
[TBL] [Abstract][Full Text] [Related]
14. CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma.
Ghuwalewala S; Ghatak D; Das P; Dey S; Sarkar S; Alam N; Panda CK; Roychoudhury S
Stem Cell Res; 2016 Mar; 16(2):405-17. PubMed ID: 26926234
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
[TBL] [Abstract][Full Text] [Related]
17. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.
Pan Q; Li Q; Liu S; Ning N; Zhang X; Xu Y; Chang AE; Wicha MS
Stem Cells; 2015 Jul; 33(7):2085-92. PubMed ID: 25873269
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties.
Lee CR; Lee SH; Rigas NK; Kim RH; Kang MK; Park NH; Shin KH
Carcinogenesis; 2016 Feb; 37(2):119-128. PubMed ID: 26645717
[TBL] [Abstract][Full Text] [Related]
19. CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics.
Noto Z; Yoshida T; Okabe M; Koike C; Fathy M; Tsuno H; Tomihara K; Arai N; Noguchi M; Nikaido T
Oral Oncol; 2013 Aug; 49(8):787-95. PubMed ID: 23768762
[TBL] [Abstract][Full Text] [Related]
20. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
